GLP-1 medications have changed the conversation around weight management, blood sugar, and metabolic health. Semaglutide and tirzepatide can be legitimate, effective medications when prescribed and monitored by a qualified clinician. But the medication is only one part of the decision. Before you start, you should also ask:

• What side effects are people experiencing outside clinical trials?
• Is the product FDA-approved or compounded?
• How do I know the medication is authentic?
• What happens if I experience unusual fatigue, menstrual changes, or temperature symptoms?
• Who is monitoring my bloodwork and overall health?
• Am I being offered an investigational peptide that is not legally available?

At Posh Fitness, we believe better health decisions begin with better information. We are not here to create fear. We are here to help you ask smarter questions.

The Real-World Side Effects That May Not Appear in a Trial

Clinical trials are essential. They help researchers measure safety and effectiveness under controlled conditions. But real-world patients may describe symptoms that are not always emphasized in trial summaries or medication advertisements. A 2026 Nature Health study analyzed 410,198 Reddit posts published between May 2019 and June 2025. Researchers identified 67,008 users who self-reported taking semaglutide or tirzepatide. About 43.5% described at least one side effect (Sehgal et al., 2026). The most common reports included:

• Nausea: 36.9%
• Fatigue: 16.7%
• Vomiting: 16.3%
• Constipation: 15.3%
• Diarrhea: 12.6%

The study also identified less-discussed patterns, including:

• Menstrual irregularities and other reproductive symptoms
• Chills and feeling unusually cold
• Hot flashes and other temperature-related complaints

Nearly 4% of people reporting side effects mentioned menstrual or reproductive symptoms in the analysis. These reports do not prove that the medication caused every symptom. Social media data can include self-diagnosis, incomplete medical histories, and unverified medication sources. Still, these signals are worth discussing with your physician. Fatigue, cycle changes, or temperature symptoms should not automatically be dismissed as “normal.” They also should not cause panic. The right response is to document what is happening and let a licensed clinician determine whether the medication, dose, another health condition, rapid weight loss, or a separate factor may be involved.

The Product Source May Matter as Much as the Medication

One of the most important GLP-1 safety questions is simple: Where did this medication come from? FDA-approved semaglutide and tirzepatide products are reviewed for safety, effectiveness, manufacturing quality, labeling, and dosage. Compounded versions are different. They are not FDA-approved, and the FDA does not review them in the same way before they are marketed. As of May 31, 2026, the FDA reported 990 adverse-event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide: more than 1,700 reports combined (U.S. Food and Drug Administration [FDA], 2026a). An adverse-event report does not prove that the drug caused the event. However, the volume is significant enough to take seriously. Reported concerns include:

• Incorrect measurements from multidose vials
• Confusion between milligrams, milliliters, and syringe units
• Doses five to 20 times higher than intended in some reports
• Contamination or inadequate sterility
• Medication arriving warm after shipping
• Incorrect or fraudulent pharmacy labels
• Unclear storage instructions
• Unknown impurity profiles
• Unapproved salt forms, such as semaglutide sodium or semaglutide acetate

The FDA has also warned that some compounded products may not contain the same active ingredient used in approved medications. Light exposure, temperature changes, and unstable packaging can affect peptide medications and potentially alter potency or degradation products. The FDA has moved to restrict semaglutide from certain compounding pathways after shortages ended and has issued warning letters involving fraudulent labeling and unapproved marketing. This does not mean every compounded product is automatically harmful. It does mean you should not assume that “compounded” means “the same as the FDA-approved medication.” Before using any prescription injection, ask:

1. Is this FDA-approved?
2. What pharmacy dispensed it?
3. Is the pharmacy state-licensed?
4. What are the exact ingredients and concentration?
5. How should it be stored?
6. Who do I contact if I have a dosing or side-effect question?

Deep discounts, no medical screening, no prescription, unclear labels, and online sellers offering “research use only” products are major warning signs.

Retatrutide Is Not a Legal Shortcut

Retatrutide is sometimes marketed online as “Triple-G.” It is an investigational drug that activates three hormone pathways: GLP-1, GIP, and glucagon. It remains in Phase III clinical trials. It is not FDA-approved for weight loss or any other indication. The FDA states that retatrutide cannot be used in compounding under federal law because it is not a component of an FDA-approved medication and has not been found safe and effective for any condition (FDA, 2026a). That means there is no legitimate retail path to obtain retatrutide outside an authorized clinical trial. Yet online peptide sellers, medical spas, and some clinics continue to advertise it. Products may be labeled “research use only,” while websites provide injection instructions or weight-loss claims. That language does not make the product safe or legal. Eli Lilly, which is developing retatrutide, has filed lawsuits against multiple companies accused of selling unauthorized versions. The concern is not only legal. Black-market products may have unknown identity, purity, concentration, sterility, and storage history. Reports involving unverified peptide products have included serious medical problems such as hospitalization, kidney injury, liver toxicity, and cardiac symptoms. These reports should not be confused with established safety findings from trial-grade retatrutide. The larger point is that a product sold outside the regulated supply chain cannot be evaluated with the same confidence as a clinical-trial medication. Do not buy retatrutide, GLP-1s, or injectable peptides from gray-market sources.

The 40+ Question: Testosterone for Menopausal Women

Hormone conversations are also changing quickly. There is currently no FDA-approved testosterone therapy for women in the United States. Testosterone may be prescribed off-label in carefully selected cases, most commonly for postmenopausal women with clinically diagnosed hypoactive sexual desire disorder. However, prescriptions for women reportedly increased approximately 146% between January 2023 and July 2026 (Reuters, 2026). Some women receive products originally designed for men, split doses, pellets, or compounded formulations. That creates practical concerns around:

• Accurate dosing
• Reliable testosterone testing
• Supraphysiologic exposure
• Acne and increased facial or body hair
• Voice changes
• Lipid changes
• Cardiovascular risk
• Breast health
• Long-term safety

On September 17, 2026, the FDA held a public workshop on testosterone use in menopausal women. The agency identified major evidence gaps involving sexual function, cognition, mood, musculoskeletal health, testing methods, cardiovascular safety, and breast cancer risk (FDA, 2026b). The workshop was not an approval meeting. It was an opportunity to examine the evidence and identify what still needs to be studied. This is exactly why hormone decisions should not be based on social media, a friend’s protocol, or a one-time lab result. You need a qualified clinician who understands your symptoms, medical history, medications, laboratory values, and long-term risk profile.

What to Do Before You Start a GLP-1

A safer, more informed process begins with a checklist.

1. Work with a licensed clinician

Prescription medications, dosing, titration, contraindications, and side-effect management belong to your physician or other qualified prescriber. Posh Fitness does not prescribe medication or provide clinical advice.

2. Verify the medication and pharmacy

Use a state-licensed pharmacy. Confirm the medication name, concentration, storage requirements, expiration date, and instructions. Avoid products sold without a prescription or marketed as research chemicals.

3. Track more than your body weight

Weight is one useful measurement. It is not the complete picture. With your healthcare team, consider tracking:

• Body composition
• Waist measurement
• Bloodwork
• Blood pressure
• Sleep quality
• Energy
• Grip strength
• VO₂ max or aerobic fitness
• Training performance
• Digestive symptoms
• Menstrual or reproductive changes, when relevant

4. Pair medication with a strong foundation

A medication should support a broader health plan that includes resistance training, adequate protein, hydration, sleep, and nutrient-dense food. This is not about extreme workouts. It is about creating a structure that helps you improve health, function, and confidence while your physician monitors the medical side.

5. Interpret your data in context

Genetics and bloodwork do not replace medical care. They can help personalize the training, nutrition, and lifestyle side of your plan. Through DNA fitness coaching, we help clients understand how their genetic tendencies may relate to nutrition, exercise response, nutrient needs, and recovery. We also offer SystemAge testing, which profiles 460 biomarkers across 21 biological systems. Additionally, we offer the most thorough gut health test available to analyze any gut microbiome issues that can affect overall health. The goal is not to chase a single number. It is to identify useful patterns that can guide better conversations and more targeted lifestyle decisions.

We Are Longevity Coaches, Not Regular Trainers

A regular trainer may focus primarily on workouts. A longevity coach looks at the larger picture. At Posh Fitness, Peter Marino helps connect your training, nutrition, bloodwork, DNA data, recovery, and measurable health goals. For clients in Fairfield County CT, that may include in-home training. We also work with clients in Greenwich CT and provide national virtual coaching. Our approach is designed for people who want more than a generic workout plan:

• Elite personal training in the comfort of your home
• Ultra personal training built around your schedule and goals
• Virtual health coaching through the Posh Fitness app
• DNA-informed nutrition and fitness recommendations
• SystemAge and bloodwork interpretation for lifestyle planning
• Ongoing tracking and accountability

For medical weight management, peptides, and hormone therapy, Posh Fitness partners with GameDay Men’s Health, where licensed clinicians evaluate eligibility and oversee medical decisions. We help support the training, nutrition, lifestyle, and data-tracking side of the plan. The goal is not to tell you what medication to take. The goal is to help you ask better questions, understand your data, and build a complete plan with the right professionals involved.

The Bottom Line

GLP-1 medications may be valuable tools. But no medication should be treated as a shortcut around medical oversight. Before you begin, verify the source. Understand the evidence. Track symptoms. Monitor objective health markers. Avoid gray-market products. And make sure your physician knows about every medication, peptide, supplement, and hormone you are using. Good health decisions do not require panic. They require context, qualified guidance, and a plan built around your biology.

Medical Disclaimer

This article is for educational purposes only. Posh Fitness does not prescribe medications, diagnose medical conditions, determine dosing, or provide clinical advice. Medical decisions and side-effect management must be handled by your licensed healthcare provider. If you experience severe or persistent symptoms, seek prompt medical care.

References

Eli Lilly and Company. (2026). Lilly calls on online platforms, payment companies, and regulators to help combat illegal retatrutide sales. https://investor.lilly.com/news-releases/news-release-details/lilly-calls-online-platforms-payment-companies-and-regulators Reuters. (2026, September 15). Testosterone prescriptions for women rise along with denials and delays. https://www.reuters.com/business/healthcare-pharmaceuticals/testosterone-scripts-women-rise-along-with-denials-delays-2026-09-15/ Sehgal, N. K. R., Tronieri, J. S., Ungar, L., & Guntuku, S. C. (2026). Self-reported side effects of semaglutide and tirzepatide in online communities. Nature Health, 1, 806–811. https://doi.org/10.1038/s44360-026-00108-y U.S. Food and Drug Administration. (2026a). FDA’s concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss U.S. Food and Drug Administration. (2026b). FDA public meeting: Testosterone use in menopausal women: September 17, 2026. https://www.fda.gov/consumers/womens-health-events/fda-public-meeting-testosterone-use-menopausal-women-09172026 U.S. Food and Drug Administration. (2026c). FDA alerts health care providers, compounders, and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skjøth, T. V., & Garvey, W. T. (2021). Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831